Company intelligence / Profile preview

SigmaDrugs Ltd.

Budapest, Budapest, Hungarysigmadrugs.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

SigmaDrugs has completed preclinical studies on its lead programs targeting chronic fibrotic diseases using novel Sigma-1 receptor agonists. The company also holds patents for an innovative organ preservation solution designed to improve graft protection and transplantation outcomes. Patents have been granted in the US, Europe, Israel, China, and Japan. No clinical trial results are yet available.

Therapeutic areas: Other
Modalities: Small molecules (specifically, Sigma-1 receptor agonists)
Industry: Biotech

Beyond the preview

Go deeper on SigmaDrugs Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SigmaDrugs Ltd..

Explore the full profile